Search

Displaying results 81 - 90 of 6090 in total
  1. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

    Categories: Biologics for Rheumatoid Arthritis TreatmentProducts: KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG, KEVZARA Solution for Injection in Pre-filled Pen 150mg
  2. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

    Products: LEQEMBI 100mg/mL concentrate for solution for infusion (2mL), LEQEMBI 100mg/mL concentrate for solution for infusion (5mL)
  3. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012. … It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk

    Categories: Drugs for Treatment of Bone DiseasesProducts: XGEVA 120mg Solution for Injection, XGEVA Solution for Injection 120 mg/vial
  4. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    [L146011] It is the first approved immunotherapy-based adjuvant regimen for Stage III dMMR colon cancer. … Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma, muscle

    Products: TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 840MG/14ML, Tecentriq 60mg/ml Concentrate for Solution for Infusion
  5. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

    Products: Bleomycin for Injection, BLEOSOL (BLEOMYCIN POWDER FOR SOLUTION FOR INJECTION / INFUSION 15 UNITS)
  6. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] The treatment effect was maintained for up to 12 months.[L2933] … Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that

    Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaProducts: LOKELMA POWDER FOR ORAL SUSPENSION 5G, LOKELMA POWDER FOR ORAL SUSPENSION 10G
  7. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]

    Products: KYPROLIS POWDER FOR SOLUTION FOR INFUSION 60MG/VIAL, KYPROLIS POWDER FOR SOLUTION FOR INFUSION 30 MG/VIAL
  8. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. … Epoetin alfa biosimilar, such as Retacrit (epoetin alfa-epbx or epoetin zeta), has been formulated to allow more access to treatment options for patients in the market [L2784].

    Products: FER, FER
  9. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reacti...

    Products: Xolair 75mg Powder and Solvent for Solution for Injection, Xolair 150mg Powder and Solvent for Solution for Injection
  10. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)